Form 4 for MBIO MUSTANG BIO, INC.
Accepted 2024-01-03 00:00:00 ET · period of report 2024-01-02 · accession 0001104659-24-000859 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-03 | 2024-01-02 | MBIO | Fortress Biotech, Inc. | 10% | A - Grant | $0.00 | +419.1K | 1.93M | +28% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK, PAR VALUE $0.0001 | 2024-01-02 | A | A | 419,092 | $0.00 | 1,927,800 | D | — | — | (F2) The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. 66,003 shares were granted by the Issuer to the Reporting Person following the closing of equity financings. (F3) The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 353,089 shares were granted by the Issuer to the Reporting Person for the 2023 annual dividend. (F1) Effective April 3, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. |